{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:14:46Z","timestamp":1781921686357,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T00:00:00Z","timestamp":1386633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s12094-013-1146-6","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T08:14:58Z","timestamp":1386576898000},"page":"776-782","source":"Crossref","is-referenced-by-count":17,"title":["Expression of Wilms\u2019 tumor gene (WT1) is associated with survival in malignant pleural mesothelioma"],"prefix":"10.1007","volume":"16","author":[{"given":"S.","family":"Cedr\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Torrejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gabaldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ramon y Cajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,10]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0003-4975(10)60182-8","volume":"43","author":"N Martini","year":"1987","unstructured":"Martini N, McCormack PM, Bains MS, Kaser LR, Burt ME, Hilaris BS, et al. Pleural mesothelioma. Ann Thorac Surg. 1987;43:113\u201320.","journal-title":"Ann Thorac Surg"},{"issue":"14","key":"1146_CR2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"key":"1146_CR3","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP Van Meerbeeck","year":"2005","unstructured":"Van Meerbeeck JP, Gaafar R, Manegold C, VanKlaveren R, VanMarck E. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1146_CR4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","volume":"16","author":"D Curran","year":"1998","unstructured":"Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for research and treatment of Cancer experience. J Clin Oncol. 1998;16(1):145.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1146_CR5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","volume":"55","author":"JG Edwards","year":"2000","unstructured":"Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O\u2019Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731.","journal-title":"Thorax"},{"key":"1146_CR6","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","volume":"16","author":"S Kao","year":"2010","unstructured":"Kao S, Pavlakis N, Harvie R, Vardy J, Boyer M, Zandwijk N, et al. High blood neutropil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16:5805\u201313.","journal-title":"Clin Cancer Res"},{"key":"1146_CR7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5858\/2008-132-397-AOITTD","volume":"232","author":"AM Marchevsky","year":"2008","unstructured":"Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;232:397\u2013401.","journal-title":"Arch Pathol Lab Med"},{"key":"1146_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2006.08.010","volume":"38","author":"NG Ordo\u00f1ez","year":"2007","unstructured":"Ordo\u00f1ez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38:1\u201316.","journal-title":"Hum Pathol"},{"key":"1146_CR9","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","volume":"6","author":"S Kao","year":"2011","unstructured":"Kao S, Klebe S, Henderson D, Reid G, Chatfield M, Armstrong NJ, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011;6:1923\u20139.","journal-title":"J Thorac Oncol"},{"key":"1146_CR10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/dc.20747","volume":"36","author":"R Pu","year":"2008","unstructured":"Pu R, Pang Y, Michael C. Utility of WT-1, p63, MOC31, mesothelin and cytokeratin (K903 and CK5\/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36:20\u20135.","journal-title":"Diagn Cytopathol"},{"key":"1146_CR11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2011.04108.x","volume":"60","author":"A Scattone","year":"2012","unstructured":"Scattone A, Serio G, Marzullo A, Nazzaro P, Corsi F, Cocca M, et al. High Wilm\u2032s tumour gene (WT1) expression and low mitotic count are independent predictors of survival im diffuse peritoneal mesothelioma. Histopathology. 2012;60:472\u201381.","journal-title":"Histopathology"},{"key":"1146_CR12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z","volume":"181","author":"S Kumar-Singh","year":"1997","unstructured":"Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell type transition, and prognosis. J Pathol. 1997;181:67\u201374.","journal-title":"J Pathol"},{"key":"1146_CR13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","volume":"57","author":"K Kushitani","year":"2007","unstructured":"Kushitani K, Takeshima Y, Amatya V, Furonaka O, Sakatani A, Inai K, et al. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int. 2007;57:190\u20139.","journal-title":"Pathol Int"},{"key":"1146_CR14","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500\u20138.","journal-title":"Cancer Res"},{"key":"1146_CR15","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.94.15.8132","volume":"94","author":"GB Silberstein","year":"1997","unstructured":"Silberstein GB, Van Horn K, Strickland P, Roberts C, Daniel C. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA. 1997;94:8132\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1146_CR16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/01.MP.0000028646.03760.6B","volume":"15","author":"DF Carpentieri","year":"2002","unstructured":"Carpentieri DF, Nichols K, Chou PM, Mathews M, Pawel B, Huff D, et al. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol. 2002;15:1080\u20136.","journal-title":"Mod Pathol"},{"key":"1146_CR17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1349-7006.2003.tb01507.x","volume":"94","author":"Y Oji","year":"2003","unstructured":"Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, et al. Overexpression of the Wilms\u2019 tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 2003;94:712\u20137.","journal-title":"Cancer Sci"},{"key":"1146_CR18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2176\/nmc.47.165","volume":"47","author":"T Hashiba","year":"2007","unstructured":"Hashiba T, Izumoto S, Kagawa N, Suzuki T, Hashimoto N, Maruno M, et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir. 2007;47:165\u201370.","journal-title":"Neurol Med Chir"},{"key":"1146_CR19","first-page":"1691","volume":"29","author":"S Ohno","year":"2009","unstructured":"Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N, et al. Immunohistochemical detection of WT1 protein in endometrial cancer. Anticancer Res. 2009;29:1691\u20136.","journal-title":"Anticancer Res"},{"key":"1146_CR20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2559.2000.00770.x","volume":"36","author":"J Oates","year":"2000","unstructured":"Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341\u20137.","journal-title":"Histopathology"},{"key":"1146_CR21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.5858\/2001-125-1316-IAONVC","volume":"125","author":"MR Foster","year":"2001","unstructured":"Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesothelioma and primary pulmonary adenocarcinomas. Arch Pathol Lab Med. 2001;125:1316\u201320.","journal-title":"Arch Pathol Lab Med"},{"key":"1146_CR22","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00000478-200308000-00001","volume":"27","author":"NG Ordo\u00f1ez","year":"2003","unstructured":"Ordo\u00f1ez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031\u201351.","journal-title":"Am J Surg Pathol"},{"key":"1146_CR23","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht T. The prioritization of cancer antigens: a national cancer institute project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323\u201337.","journal-title":"Clin Cancer Res"},{"key":"1146_CR24","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","volume":"13","author":"RJ May","year":"2007","unstructured":"May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang R, et al. Peptide epitopes from the Wilms\u2019 tumour 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13:4547\u201355.","journal-title":"Clin Cancer Res"},{"key":"1146_CR25","doi-asserted-by":"crossref","unstructured":"Krug LM, Tsao AS, Kass S. Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 2011;29(Suppl):abst TPS139.","DOI":"10.1200\/jco.2011.29.15_suppl.tps139"},{"key":"1146_CR26","unstructured":"NCT01265433 randomized study of adjuvant study of adjuvant WT-1 analog peptide vaccine in patients with malignant pleural mesothelioma (MPM) after completion of combined modality therapy."},{"key":"1146_CR27","unstructured":"NCT01890980 phase II study of adjuvant WT-1 analog peptide vaccine in MPM patients after MSK 10-134."},{"key":"1146_CR28","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","volume":"13","author":"A Cristaudo","year":"2007","unstructured":"Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13:5076\u201381.","journal-title":"Clin Cancer Res"},{"key":"1146_CR29","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","volume":"66","author":"F Lopez-Rios","year":"2006","unstructured":"Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei P, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970\u20139.","journal-title":"Cancer Res"},{"key":"1146_CR30","first-page":"3080","volume":"9","author":"S Singhal","year":"2003","unstructured":"Singhal S, Wiewrodt R, Malden L, Amin K, Matzie K, Friedberg J, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res. 2003;9:3080\u201397.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-013-1146-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-013-1146-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-013-1146-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T07:33:11Z","timestamp":1647675191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-013-1146-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,10]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1007\/s12094-013-1146-6","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,10]]}}}